DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism.

DCB-3503, a tylophorine analog, inhibits protein synthesis through a novel mechanism.
复制标题

DOI:
10.1371/journal.pone.0011607
复制
发表时间:
2010-07-15
期刊:
影响因子:
3.7
通讯作者:
Cheng YC
Cheng YC
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Wang Y;Gao W;Svitkin YV;Chen AP;Cheng YC

文献摘要

参考文献

被引文献

相似文献

DCB-3503, a tylophorine analog, inhibits the growth of PANC-1 (human pancreatic ductal cancer cell line) and HepG2 (human hepatocellular cancer cell line) tumor xenografts in nude mice. The inhibition of growth leads to cancer cell differentiation instead of cell death. However, the mechanisms of action of tylophorine analogs is unknown. In this study, we show that DCB-3503 suppresses the expression of pro-oncogenic or pro-survival proteins with short half-lives, including cyclin D1, survivin, β-catenin, p53, and p21, without decreasing their mRNA levels. Proteasome inhibitor reversed the inhibitory effect of DCB-3503 on expression of these proteins. DCB-3503 inhibited the incorporation of radiolabeled amino acid and thymidine, and to a much lesser degree of uridine, in a panel of cell lines. The mechanism of inhibition of protein synthesis is different from that of cycloheximide (CHX) as assayed in cell culture and HeLa in vitro translation system. Furthermore, in contrast to rapamycin, DCB-3503 does not affect protein synthesis through the mTOR pathway. DCB-3503 treatment shifts the sedimentation profiles of ribosomes and mRNAs towards the polysomal fractions while diminishing monosome abundance, indicative of the inhibition of the elongation step of protein synthesis. Preferential down regulation of several studied proteins under these conditions is likely due to the relative short half-lives of these proteins. The inhibitory effect of DCB-3503 on translation is apparently distinct from any of the current anticancer compounds targeting protein synthesis. Translation inhibitors with novel mechanism could complement current chemotherapeutic agents for the treatment of human cancers and suppress the occurrence of drug resistance.
DOI: 10.1124/mol.106.028480
发表时间: 2006-12-01
影响因子: 3.6
作者:
Leung, Chung-Hang;Grill, Susan P.;Cheng, Yung-Chi
通讯作者: Cheng, Yung-Chi
DOI: 10.1158/0008-5472.can-07-2416
发表时间: 2007-11-15
期刊: CANCER RESEARCH
影响因子: 11.2
作者:
Mertens-Talcott, Susanne U.;Chintharlapalli, Sudhakar;Safe, Stephen
通讯作者: Safe, Stephen
DOI: 10.1016/j.bmcl.2007.05.021
发表时间: 2007-08-01
影响因子: 2.7
作者:
Gao, Wenli;Bussom, Scott;Cheng, Yung-Chi
通讯作者: Cheng, Yung-Chi
DOI: 10.1124/mol.57.3.529
发表时间: 2000-03-01
影响因子: 3.6
作者:
Budihardjo, II;Boerner, SA;Kaufmann, SH
通讯作者: Kaufmann, SH
DOI: 10.1126/science.277.5322.99
发表时间: 1997-07-04
期刊: SCIENCE
影响因子: 56.9
作者:
Brunn, GJ;Hudson, CC;Abraham, RT
通讯作者: Abraham, RT